Printer Friendly

DOD awards axogen funding for stem cell research on peripheral nerve repair.

ALACHUA, Fla., June 4, 2014--AxoGen, Inc. (AXGN) said it will share in the award of two Department of Defense Grants totaling approximately $ 1.9 million with Brigham and Women's Hospital in Boston (BWH).

Part of the funding will be used to explore the promise of stem cell therapies in combination with Avance Nerve Graft, a processed human nerve allograft currently marketed by AxoGen, to enhance nerve regeneration.

A second part will study the development of branched peripheral nerve allografts to help improve the aesthetic and functional outcomes of complex facial injuries.

During complex reconstructions, manually recreating branching nerve segments is both time consuming and technically challenging. This grant provides the opportunity to develop a branched nerve allograft product for implantation.

The two grants will be funded through the Congressionally Directed Medical Research Program.

Avance Nerve Graft is an off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site. AxoGuard Nerve Connector is a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves. AxoGuard Nerve Protector is a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance Nerve Graft is processed in the United States by AxoGen. AxoGuard Nerve Connector and AxoGuard Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed exclusively by AxoGen.


COPYRIGHT 2014 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Grants & Contracts
Publication:Stem Cell Business News
Date:Jun 16, 2014
Previous Article:New $30 million equity facility for NeoStem.
Next Article:Cell-based assays market by product.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters